Vi­a­tris and Bio­con mull pool­ing their biosim­i­lars in­to a $10B stand­alone com­pa­ny — re­port

Vi­a­tris (My­lan/Pfiz­er’s Up­john) and In­dia’s Bio­con Bi­o­log­ics are re­port­ed­ly pon­der­ing whether to fur­ther en­twine their biosim­i­lar busi­ness­es in­to a $10 bil­lion stand­alone com­pa­ny, ac­cord­ing to sources from Nisha Pod­dar at an In­di­an af­fil­i­ate of CN­BC.

Ear­li­er this sum­mer, the two com­pa­nies won the first high­ly-cov­et­ed in­ter­change­abil­i­ty des­ig­na­tion for their biosim­i­lar Sem­glee, which is an in­sulin that’s in­ter­change­able with Sanofi’s Lan­tus. Al­though, in a bizarre twist with the way the US in­sulin mar­ket works, the com­pa­nies had to launch two ver­sions of the in­ter­change­able — one at a 65% dis­count, and one at a much high­er price in or­der to gain mar­ket share.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER